Stability of polycationic complexes of an antisense oligonucleotide in rat small intestine homogenates

Ferreiro, Marı́a González; Crooke, Rosanne M.; Tillman, Lloyd; Hardee, Gregory E.; Bodmeier, Roland

doi:10.1016/s0939-6411(02)00140-6

Search citation statements

Order By: Relevance

Paper Sections

Select...

Allergen-specific Immunotherapy1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2007

2023

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 18 publications

(1 citation statement)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pharmaceutically, it has been used to preserve plasmid DNA for gene transfer (34) and to avoid degradation of oligodeoxynucleotides (35). Pharmaceutically, it has been used to preserve plasmid DNA for gene transfer (34) and to avoid degradation of oligodeoxynucleotides (35).…”

Section: Allergen-specific Immunotherapymentioning

confidence: 99%

A Protective Allergy Vaccine Based on CpG- and Protamine-Containing PLGA Microparticles

et al. 2007

View full text Add to dashboard Cite

show abstract

Section: Allergen-specific Immunotherapymentioning

confidence: 99%

A Protective Allergy Vaccine Based on CpG- and Protamine-Containing PLGA Microparticles

et al. 2007

View full text Add to dashboard Cite

show abstract

Antisense Oligonucleotide (AS‐ODN) Technology: Principle, Mechanism and Challenges

Gheibihayat

Jamialahmadi

2020

Biotech and App Biochem

View full text Add to dashboard Cite

Recently, there is a hopefully tremendous interest in antisense therapeutics for clinical purposes. Single‐stranded synthetic antisense oligonucleotides (As‐ODNs) with monomers of chemically modified 18–21 deoxynucleotides complement the mRNA sequence in target gene. The target gene expression can be blocked because of created cleavage or disability of the mRNA by binding the As‐ODNs to cognate mRNA sequences via sequence‐specific hybridization. The idea of antisense therapy has become particular concerning that any sequence longer than a minimal number of nucleotides (17 for DNA and 13 for RNA) can be observed only once within the human genome. The mRNA is omnipresent more probably to manipulate compared to DNA, which results in multiple in vitro and in vivo applications for As‐ODNs in the field of regulatory mechanisms of biological processes, cancer, viral infections and hereditary impairments. Although, there are uncertain clinical outcomes on the ability of this approach in treatment procedures despite achieving promising findings based on previous investigations. Accordingly, the efficacy, off‐target effects, delivery are issues that should be investigated to obtain satisfactory results. In this review, we will explain the mechanism of action of As‐ODNs and various types of modifications and their therapeutic purposes.

show abstract

Ternary Polymeric Nanoparticles for Oral siRNA Delivery

Zhang

Tang

et al. 2013

Pharm Res

View full text Add to dashboard Cite

show abstract

Stability of polycationic complexes of an antisense oligonucleotide in rat small intestine homogenates

Cited by 18 publications

References 29 publications

A Protective Allergy Vaccine Based on CpG- and Protamine-Containing PLGA Microparticles

A Protective Allergy Vaccine Based on CpG- and Protamine-Containing PLGA Microparticles

Antisense Oligonucleotide (AS‐ODN) Technology: Principle, Mechanism and Challenges

Ternary Polymeric Nanoparticles for Oral siRNA Delivery

Contact Info

Product

Resources

About